Bristol-Myers Squibb Company (BMY)
NYSE • Healthcare
November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Bristol-Myers Squibb Company keeps $17 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 4
in 77 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Bristol-Myers Squibb beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with adjusted EPS of $1.35 topping the $1.10 estimate (+22.7%) as revenue of $13.069 billion topped the $12.723 billion consensus (+2.7%). Revenue rose ~7% to about $13.1 billion (up from $12.222 billion a year ago), led by Net product sales, which increased ~6% to roughly $12.6 billion, while smaller lines were mixed, with Other revenues rising ~49% to about $368 million and Alliance revenues down ~24% to roughly $95 million. Profitability included gross profit of about $8.9 billion, translating to a gross margin of roughly 68%, and operating income of about $2.8 billion with operating margin near 22%. Net income edged down ~2% year over year to about $2.2 billion (from $2.201 billion), alongside adjusted EPS down ~17% from $1.63 a year ago despite the quarter’s consensus beat. The company generated operating cash flow of roughly $4.2 billion and paid about $1.3 billion in dividends. For the next period, consensus calls for EPS of $1.63 on revenue of $12.692 billion.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) develops, manufactures, and sells prescription medicines as a large biopharmaceutical company in healthcare. Across hematology, cancer, cardiovascular, immune, neurological, fibrotic, and infectious-disease treatment areas, it generated $48.2 billion of revenue in FY2025 through a portfolio that spans oncology, immunology, and cardiovascular therapies.
Today's Snapshot
The day ended with BMY 2.9% lower at 59.56, in line with a weaker sector. Bristol-Myers Squibb raised its 2026 profit forecast.
Trading Volume
Above 10d avg 9.3M
9.5M
vs S&P 500 Today
Underperforming Market
-2.66%
Updated: November 18, 2026 at 21:25 UTC
BMY Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$59.59 - $61.96Sell
- RSI (14)40.87Neutral
- Stochastic %K (14, 3, 3)26.19Neutral
- MACD Level (12, 26)0.05Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.